Clinicopathological characteristics among 36 patients with different mutation status
| Features | n | BRCA+ (n = 9, %) | non-BRCA+ (n = 20, %) | Negative (n = 7, %) | P1-value* | P2-value* |
|---|---|---|---|---|---|---|
| Age of onset (years) | ||||||
| Mean ± size | 44.8 ± 9.5 | 55.7 ± 10.3 | 51.3 ± 6.8 | 0.148a | 0.307a | |
| ≤ 45 | 8 | 5 (55.6%) | 1 (5.0%) | 2 (28.6%) | 0.358 | 0.156 |
| > 45 | 28 | 4 (44.4%) | 19 (95.0%) | 5 (71.4%) | ||
| Unilateral/bilateral | 0.088 | 1.000 | ||||
| Unilateral | 31 | 5 (55.6%) | 19 (95.0%) | 7 (100.0%) | ||
| Bilateral | 5 | 4 (44.4%) | 1 (5.0%) | 0 (0.0%) | ||
| Tumor size | 0.550 | 1.000 | ||||
| ≤ 3 cm | 28 | 8 (88.9%) | 15 (75.0%) | 5 (71.4%) | ||
| > 3 cm | 8 | 1 (11.1%) | 5 (25.0%) | 2 (28.6%) | ||
| Axillary lymph node metastasis | 0.049 | 1.000 | ||||
| Yes | 16 | 7 (77.8%) | 7 (35.0%) | 2 (28.6%) | ||
| No | 20 | 2 (22.2%) | 13 (65.0%) | 5 (71.4%) | ||
| TNM stage | 0.263b | 0.435b | ||||
| 0 + I | 17 | 2 (22.2%) | 10 (50.0%) | 5 (71.4%) | ||
| II | 14 | 7 (77.8%) | 6 (30.0%) | 1 (14.3%) | ||
| III | 5 | 0 (0.0%) | 4 (20.0%) | 1 (14.3%) | ||
| Tumor grade | 0.109b | 0.665b | ||||
| I | 8 | 1 (11.1%) | 5 (25.0%) | 2 (28.6%) | ||
| II | 23 | 8 (88.9%) | 12 (60.0%) | 3 (42.9%) | ||
| III | 5 | 0 (0.0%) | 3 (15.0%) | 2 (28.6%) | ||
| Histological type | 1.000 | 0.633 | ||||
| Breast invasive ductal carcinoma | 28 | 7 (77.8%) | 16 (80.0%) | 5 (71.4%) | ||
| Other | 8 | 2 (22.2%) | 4 (20.0%) | 2 (28.6%) | ||
| Luminal type | 0.086b | 0.160b | ||||
| Luminal A | 4 | 0 (0.0%) | 3 (15.0%) | 2 (28.6%) | ||
| Luminal B | 21 | 6 (66.7%) | 12 (60.0%) | 5 (71.4%) | ||
| HER2 overexpressing | 4 | 0 (0.0%) | 4 (20.0%) | 0 (0.0%) | ||
| Triple negative | 4 | 3 (33.3%) | 1 (5.0%) | 0 (0.0%) | ||
| With benign breast disease | 0.060 | 0.024 | ||||
| Yes | 21 | 6 (66.7%) | 14 (70.0%) | 1 (14.3%) | ||
| No | 15 | 3 (33.3%) | 6 (30.0%) | 6 (85.7%) | ||
| Recurrence or metastasis | 1.000 | 1.000 | ||||
| Yes | 2 | 1 (11.1%) | 1 (5.0%) | 0 (0.0%) | ||
| No | 34 | 8 (88.9%) | 19 (95.0%) | 7 (100.0%) | ||
*Fisher’s precise test; aStudent’s t-test; brank-sum test; P1-value: BRCA+ group vs. the negative group; P2-value: non-BRCA+ group vs. the negative group.